BTK and susceptibility to pneumonia measurement: Therefore, future studies can focus on the integration of COVID-19, SARS-CoV-2, bronchial epithelial cells, and transcriptomic analysis in lymphoma patients, especially regarding the gene networks associated with pneumonia risk when using BTK inhibitors or anti-CD20 therapies.